1.50

5.63% 0.08

After Hours: 1.50

Pulmonx Corp (LUNG)

Overview News Price History Option Chain Financials Discussions Forecast

Pulmonx Corp stock is traded at $1.50, with a volume of 365.47K. It is up +5.63% in the last 24 hours and down -10.71% over the past month. Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Previous Close:

$1.42

Open:

$1.43

24h Volume:

365.47K

Relative Volume:

0.78

Market Cap:

$63.36M

Revenue:

$90.50M

Net Income/Loss:

$-54.00M

P/E Ratio:

-1.1282

EPS:

-1.3296

Net Cash Flow:

$-32.90M

1W Performance:

+16.28%

1M Performance:

-10.71%

6M Performance:

-6.83%

1Y Performance:

-69.51%

1-Day Range:

$1.41

$1.5099

1-Week Range:

$1.235

$1.5101

52-Week Range:

$1.13

$5.459

Pulmonx Corp Stock (LUNG) Company Profile

Name

Pulmonx Corp

Sector

Healthcare (1112)

Industry

Medical Devices (143)

Phone

650-364-0400

Address

700 CHESAPEAKE DRIVE, REDWOOD CITY

Employee

296

Twitter

Next Earnings Date

2024-10-30

Latest SEC Filings

LUNG's Discussions on Twitter

Compare LUNG vs ABT, SYK, MDT, BSX, EW

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LUNG Pulmonx Corp	1.50	59.98M	90.50M	-54.00M	-32.90M	-1.3296
ABT Abbott Laboratories	101.56	175.59B	44.33B	6.50B	7.40B	3.717
SYK Stryker Corp	341.24	132.47B	25.12B	3.25B	4.28B	8.3984
MDT Medtronic Plc	87.10	113.14B	35.48B	4.64B	5.41B	3.582
BSX Boston Scientific Corp	64.61	94.85B	20.08B	2.89B	3.66B	1.9391
EW Edwards Lifesciences Corp	78.20	45.09B	6.07B	1.06B	1.34B	1.8063

Pulmonx Corp Stock (LUNG) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-31-25	Downgrade	Piper Sandler	Overweight → Neutral
Mar-10-25	Initiated	D. Boral Capital	Buy
Dec-11-24	Downgrade	Citigroup	Buy → Neutral
Jun-04-24	Initiated	Lake Street	Buy
Feb-23-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Sep-05-23	Initiated	Craig Hallum	Buy
Feb-27-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Jan-03-23	Downgrade	BofA Securities	Neutral → Underperform
Dec-12-22	Upgrade	Citigroup	Neutral → Buy
Jul-11-22	Downgrade	Citigroup	Buy → Neutral
Mar-02-22	Resumed	BofA Securities	Neutral
Dec-08-21	Upgrade	Piper Sandler	Neutral → Overweight
Apr-01-21	Initiated	Citigroup	Buy
Mar-25-21	Initiated	Piper Sandler	Neutral
Mar-10-21	Upgrade	BofA Securities	Neutral → Buy
Jan-04-21	Downgrade	BofA Securities	Buy → Neutral
Oct-26-20	Initiated	BofA Securities	Buy
Oct-26-20	Initiated	Canaccord Genuity	Buy
Oct-26-20	Initiated	Morgan Stanley	Equal-Weight
Oct-26-20	Initiated	Stifel	Buy
Oct-26-20	Initiated	Wells Fargo	Equal Weight

View All

Pulmonx Corp Stock (LUNG) Latest News

04:05 AM

Pulmonx sets April 29 earnings release, 4:30 p.m. ET webcast - Stock Titan

04:05 AM

Apr 13, 2026

Pulmonx Corp stock (US74586W1018): Is its airway treatment edge strong enough to unlock new upside? - AD HOC NEWS

Apr 13, 2026

Apr 10, 2026

LUNG Stock Price, Quote & Chart | PULMONX CORP (NASDAQ:LUNG) - ChartMill

Apr 10, 2026

Apr 05, 2026

Pulmonx Insiders Forfeit On 14% Gains After Selling Stock - Sahm

Apr 05, 2026

Apr 04, 2026

How The Pulmonx (LUNG) Investment Story Is Shifting After Q4 And New Guidance - Yahoo Finance

Apr 04, 2026

Apr 02, 2026

Earnings call transcript: Pulmonx Q4 2025 EPS beats, revenue misses, stock dips - Investing.com

Apr 02, 2026

Mar 30, 2026

Rate Hike: Is Pulmonx Corporation stock trending bullishWeekly Profit Summary & Safe Capital Growth Plans - baoquankhu1.vn

Mar 30, 2026

Mar 27, 2026

Vanguard discloses zero Pulmonx holdings after internal realignment (NASDAQ: LUNG) - Stock Titan

Mar 27, 2026

Mar 22, 2026

If You Invested $1,000 in Pulmonx Corp (LUNG) - Stock Titan

Mar 22, 2026

Mar 21, 2026

How The Pulmonx (LUNG) Narrative Is Resetting Around Execution Risks And Fair Value Assumptions - Yahoo Finance

Mar 21, 2026

Mar 15, 2026

LUNG SEC FilingsPulmonx Corp 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 15, 2026

Pulmonx Corp Stock (ISIN: US74586W1018) Trades at Multi-Year Lows Amid Growth Potential in Lung Ther - AD HOC NEWS

Mar 15, 2026

Mar 14, 2026

Growth Value: Should I set a stop loss on Pulmonx CorporationBull Run & Real-Time Volume Analysis Alerts - baoquankhu1.vn

Mar 14, 2026

Mar 11, 2026

Pulmonx Corporation 2025 Annual Report: Innovative COPD Solutions, Zephyr Valve Clinical Data, and Global Market Strategy - Minichart

Mar 11, 2026

LUNG Technical Analysis & ETF Price Forecast - Intellectia AI

Mar 11, 2026

Mar 10, 2026

Pulmonx (NASDAQ: LUNG) expands emphysema device business but remains unprofitable - Stock Titan

Mar 10, 2026

Pulmonx 2025 10-K: Revenue $90.5M, EPS (Loss) $(1.33) - TradingView

Mar 10, 2026

Pulmonx Corporation (LUNG) Releases Q4 2025 Earnings: Revenue Down, Diluted Loss Per Share Widens - Quiver Quantitative

Mar 10, 2026

Mar 09, 2026

Soleus group holds 2.67M Pulmonx shares (LUNG) — 6.5% stake disclosed - Stock Titan

Mar 09, 2026

Mar 07, 2026

Pulmonx (LUNG) Projects 2026 Financial Outlook with Revenue and Margin Targets - GuruFocus

Mar 07, 2026

Mar 06, 2026

Pulmonx Corporation (NASDAQ:LUNG) Q4 2025 Earnings Call Transcript - Insider Monkey

Mar 06, 2026

Mar 05, 2026

Pulmonx Secures $60 Million Senior Secured Term Loan From Perceptive; $40 Million Drawn - TradingView

Mar 05, 2026